Compare BEPC & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BEPC | KYMR |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medicinal Chemicals and Botanical Products |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 6.4B |
| IPO Year | N/A | 2020 |
| Metric | BEPC | KYMR |
|---|---|---|
| Price | $38.43 | $78.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 23 |
| Target Price | $39.75 | ★ $105.35 |
| AVG Volume (30 Days) | 855.6K | ★ 1.5M |
| Earning Date | 01-30-2026 | 11-04-2025 |
| Dividend Yield | ★ 3.89% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,828,000,000.00 | $43,735,000.00 |
| Revenue This Year | $40.27 | $18.71 |
| Revenue Next Year | $9.79 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $23.73 | $19.45 |
| 52 Week High | $45.10 | $103.00 |
| Indicator | BEPC | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 42.01 | 51.31 |
| Support Level | $36.81 | $77.28 |
| Resistance Level | $39.26 | $85.41 |
| Average True Range (ATR) | 0.77 | 3.47 |
| MACD | 0.06 | -1.40 |
| Stochastic Oscillator | 53.49 | 7.35 |
Brookfield Renewable is a globally diversified, multitechnology owner and operator of clean energy assets. The company's portfolio consists of hydroelectric, wind, solar, and storage facilities in North America, South America, Europe, and Asia, and totals over 40 gigawatts of installed capacity. Brookfield Renewable invests in assets directly, as well as with institutional partners, joint venture partners, and through other arrangements. The company offers two separate listings for investors: Brookfield Renewable Partners LP and Brookfield Renewable Corp.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.